Core Viewpoint - China Tongru (01763) experienced a significant stock price increase, rising over 7% during trading and closing at 20.16 HKD, with a transaction volume of 10.36 million HKD, following the launch of its high-abundance 13CO gas and urea products, marking a milestone in the domestic production of medical stable isotopes [1] Company Overview - China Tongru is a specialized company under the China National Nuclear Corporation, focusing on nuclear technology applications, including the development, production, sales, and services related to nuclear medicine, radiation source products, and nuclear medical equipment [1] - The company has established a comprehensive layout in the nuclear medicine sector, with a network of 37 medical centers and 7 R&D production bases by December 31, 2024, positioning itself as a leading enterprise in China's nuclear medicine field [1] Industry Impact - The successful launch of the high-abundance 13CO gas and urea products signifies China's achievement in breaking the long-standing reliance on imports for the raw materials used in urea breath diagnostic tests, enabling full domestic control over the entire industry chain from key raw materials to end products [1] - This development positions China Tongru as a leading enterprise that fully masters the entire industry chain of breath test products, enhancing its competitive edge in the medical stable isotope market [1]
中国同辐盘中涨超7% 公司发布高丰度13CO气体及尿素产品 助力产业链全面自主可控